Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics, Inc. (CATX)
XASE:CATX
CATX Stock Chart & Stats
$2.81
-$0.13(-3.36%)
At close: 4:00 PM EST
$2.81
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.60 - $5.39
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.24M
Market Cap
$208.89M
Enterprise Value$231.39M
Total Cash (Recent Filing)$174.14M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 26, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding74,337,990
10 Day Avg. Volume876,978
30 Day Avg. Volume1,243,481
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue275.13
Enterprise Value/Gross Profit-165.39
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$11.83Price Target Upside321.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$888.03K
Bulls Say, Bears Say
Bulls Say
Clinical CatalystsPresentation of expanded Cohort 2 anti-tumor activity could materially boost investor confidence if additional confirmed responses and durable outcomes are reported.
Financial RunwayA cash position that supports operations into late 2026 reduces near-term financing risk and allows focus on advancing clinical programs without immediate capital raises.
Safety ProfileA consistently favorable safety profile with no grade IV treatment-related adverse events and no treatment-related discontinuations may support broader adoption and enhance valuation if sustained across larger cohorts.
Bears Say
Comparative EfficacyObjective response rates that trail leading competitor programs may limit commercial potential and prompt investor reassessment of market share prospects.
Development And Financing RiskOngoing net losses combined with competitors advancing to later-stage trials increase the risk of dilution and tougher regulatory and commercial comparisons for the program.
Market SensitivityThe pronounced sell-off after the data update demonstrates vulnerability to sentiment-driven declines if upcoming results fail to meet elevated expectations.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.60 and its highest was $5.39 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $208.89M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 73 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.029.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 74,337,990 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.83 (321.00% Upside)
$11.83 (321.00% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 45.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.39%
12-Months-Change
Fundamentals
Return on Equity
-37.24%
Trailing 12-Months
Asset Growth
-24.63%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$11.83
▲(321.00% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
17.46% Mutual Funds
11.49% Other Institutional Investors
60.03% Public Companies and
Individual Investors